Home » Stocks » KMDA

Kamada Ltd. (KMDA)

Stock Price: $5.73 USD 0.06 (1.06%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $5.69 -0.04 (-0.70%) May 14, 7:10 PM
Market Cap 261.27M
Revenue (ttm) 124.86M
Net Income (ttm) 14.61M
Shares Out 44.75M
EPS (ttm) 0.32
PE Ratio 17.85
Forward PE 44.05
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $5.73
Previous Close $5.67
Change ($) 0.06
Change (%) 1.06%
Day's Open 5.63
Day's Range 5.55 - 5.75
Day's Volume 57,394
52-Week Range 5.55 - 13.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Marc...

4 days ago - GlobeNewsWire

On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

5 days ago - Benzinga

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other stocks mentioned: BDSI, CODX, SURF, VMD
3 weeks ago - GuruFocus

Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the interim ...

1 month ago - Benzinga

REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, single-...

1 month ago - GlobeNewsWire

REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will prese...

2 months ago - GlobeNewsWire

Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

2 months ago - GlobeNewsWire

REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the...

2 months ago - GlobeNewsWire

Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Kamada (NASDAQ:KMDA) decreased 1.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 69.23% over the past year to $0.04, which missed...

3 months ago - Benzinga

REHOVOT, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months en...

3 months ago - GlobeNewsWire

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quar...

3 months ago - GlobeNewsWire

Transaction Represents Kamada's Entry into U.S. Plasma Collection Market and Advances the Company's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

3 months ago - GlobeNewsWire

Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics

4 months ago - GlobeNewsWire

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NA...

4 months ago - GlobeNewsWire

Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.

5 months ago - Zacks Investment Research

Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Kamada (NASDAQ:KMDA) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 7.14% over the past year to $0.15, which beat the estimate of $0.06.

6 months ago - Benzinga

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quart...

6 months ago - GlobeNewsWire

We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a potential dis...

6 months ago - Seeking Alpha

The biotech specializes in plasma-derived protein therapeutics.

6 months ago - The Motley Fool

REHOVOT, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has signed an agreement with the Israeli Ministr...

6 months ago - GlobeNewsWire

REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, ...

7 months ago - GlobeNewsWire

Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

Other stocks mentioned: LLY
8 months ago - The Motley Fool

Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus study of it...

8 months ago - 24/7 Wall Street

REHOVOT, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced the completion of enrollment and initial interim resu...

8 months ago - GlobeNewsWire

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: CERS, TTOO
8 months ago - Zacks Investment Research

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

Other stocks mentioned: ADMA, EBS
8 months ago - The Motley Fool

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...

Other stocks mentioned: ADMA, CERS, GRFS, LMNL, SONN, THMO, TTOO
8 months ago - Benzinga

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s o...

Other stocks mentioned: LMNL, SONN
8 months ago - Benzinga

REHOVOT, Israel and FORT LEE, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two leading biopharmaceutical companies specialized in plasma-derived pro...

8 months ago - GlobeNewsWire

Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Di...

9 months ago - GlobeNewsWire

Shares of Kamada (NASDAQ:KMDA) moved lower by 2.5% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months...

9 months ago - GlobeNewsWire

On Wednesday, August 12, Kamada (NASDAQ: KMDA) will release its latest earnings report.

9 months ago - Benzinga

REHOVOT, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that the first patient has been recruited to the Phase...

9 months ago - GlobeNewsWire

REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second qu...

9 months ago - GlobeNewsWire

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Other stocks mentioned: BURG, LMNL
9 months ago - Benzinga

Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.

9 months ago - The Motley Fool

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety

9 months ago - Seeking Alpha

Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

REHOVOT, Israel, June 17, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today provided an update on its development of a plasma-derive...

10 months ago - GlobeNewsWire

Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

About KMDA

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1990
Stock Exchange
NASDAQ
Ticker Symbol
KMDA
Full Company Profile

Financial Performance

In 2020, Kamada's revenue was $133.25 million, an increase of 4.76% compared to the previous year's $127.19 million. Earnings were $17.14 million, a decrease of -22.97%.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Kamada stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 91.97% from the latest price.

Price Target
$11.00
(91.97% upside)
Analyst Consensus: Strong Buy